# ğŸ—ºï¸ US Oncology Market Map â€” RISA Labs Strategic Ecosystem Guide

> **Purpose:** Comprehensive stakeholder map for RISA Labs (healthcare AI / oncology RCM)
> **Last Updated:** February 2026

---

## 1. ğŸ¥ CARE DELIVERY (Providers)

### 1.1 NCI-Designated Comprehensive Cancer Centers
- **Examples:** MD Anderson, Memorial Sloan Kettering, Dana-Farber, Fred Hutch, Moffitt, City of Hope
- **Role:** Research + clinical care, clinical trials, complex/rare cases
- **Revenue Model:** Grants (NCI/NIH), patient revenue, philanthropy, IP licensing
- **Scale:** ~72 NCI-designated centers (53 comprehensive)
- **Pain Points:** Grant funding uncertainty, EHR fragmentation, trial enrollment bottlenecks, complex multi-payer billing
- **RISA Opportunity:** Complex claim adjudication (multi-payer, trial vs. standard care billing), denial management for novel therapies
- **Money Flow:** â† NCI grants, patient revenue (commercial + Medicare), philanthropy â†’ staff, research, drugs
- **Data Flow:** Generates â†’ clinical trial data, genomic data, treatment outcomes; Consumes â† guidelines, payer policies

### 1.2 Academic Medical Center Cancer Programs
- **Examples:** Stanford Cancer Center, UCSF, Johns Hopkins, Mayo Clinic, Cleveland Clinic
- **Role:** Teaching + research + clinical care, tertiary/quaternary referrals
- **Pain Points:** Faculty retention, balancing research vs. clinical volume, complex referral billing
- **RISA Opportunity:** Multi-departmental charge capture, referral authorization automation
- **Money Flow:** â† Tuition, patient revenue, grants, state funding â†’ faculty, facilities, research
- **Data Flow:** Generates â†’ published research, training datasets; Consumes â† referral records, external imaging

### 1.3 Large Community Oncology Practices
- **Examples:** Texas Oncology, Florida Cancer Specialists, Regional Cancer Care Associates, Oncology Hematology Care (OHC)
- **Role:** Delivers 60%+ of US cancer care, volume-driven, closer to patients
- **Ownership:** Physician-owned, PE-backed, or health systemâ€“affiliated
- **Pain Points:** Margin pressure (drug reimbursement cuts, rising costs), payer denials, staffing shortages, pathway compliance burden
- **RISA Opportunity:** â­ **PRIMARY TARGET** â€” Prior auth automation, denial prevention, buy-and-bill optimization, coding accuracy for chemo regimens
- **Money Flow:** â† Patient copays, payer reimbursement, drug margin (buy-and-bill) â†’ staff, drug purchases, overhead
- **Data Flow:** Generates â†’ claims, treatment records, pathway adherence; Consumes â† payer policies, NCCN guidelines, drug pricing

### 1.4 Hospital System Cancer Programs
- **Examples:** HCA Healthcare, Providence, Intermountain, Northwell, CommonSpirit, Atrium
- **Role:** Integrated delivery networks, employed oncologists, inpatient + outpatient
- **Pain Points:** Oncology service line profitability, 340B optimization, employed physician productivity
- **RISA Opportunity:** Service line revenue integrity, 340B compliance, charge capture for infusion centers
- **Money Flow:** â† Payer contracts (DRG inpatient, APC outpatient), 340B savings â†’ salaries, facilities, drugs
- **Data Flow:** Generates â†’ large structured EHR datasets; Consumes â† benchmarking, quality metrics

### 1.5 Oncology Management / Network Organizations
- **US Oncology Network (McKesson)** â€” Largest; 1,400+ physicians, manages Texas Oncology, New York Oncology Hematology, etc.
  - Role: GPO, practice management, iKnowMed EHR, clinical pathways, data aggregation
- **OneOncology (TPG)** â€” PE-backed, 600+ providers, rapid acquisition strategy
  - Role: Practice management, shared services, pathways
- **American Oncology Network (AON)** â€” Physician-led, partnership model
  - Role: Back-office, analytics, value-based care support
- **Flatiron Health (Roche)** â€” OncoEMR + real-world data platform
  - Role: EHR, data licensing to pharma, research analytics
- **Pain Points:** Standardizing operations across diverse practices, demonstrating value-based care savings
- **RISA Opportunity:** Platform-level RCM integration (one integration â†’ hundreds of practices), network-wide denial analytics
- **Money Flow:** â† Management fees, GPO rebates, data licensing revenue â†’ practice support, technology
- **Data Flow:** Aggregates â† practice-level clinical + claims data; Sells â†’ de-identified data to pharma/research

---

## 2. ğŸ’° PAYERS & REIMBURSEMENT

### 2.1 Medicare / CMS
- **Role:** Largest single oncology payer (median cancer diagnosis age: 66)
- **Medicare Fee-for-Service (FFS)** â€” Traditional; pays per service
- **Medicare Advantage (MA)** â€” Managed care; ~52% of Medicare beneficiaries (2025), growing
  - Key MA oncology plans: UnitedHealthcare MA, Humana, Aetna, BCBS
- **Enhancing Oncology Model (EOM)** â€” Successor to OCM; episode-based payments, quality measures, health equity focus
  - Participating practices take on financial risk for episodes of care
- **Pain Points:** Complex coverage rules, LCD/NCD variability, slow policy updates for new therapies
- **RISA Opportunity:** â­ Medicare denial reduction (top payer = top denial volume), EOM reporting automation, MA prior auth automation
- **Money Flow:** â† Payroll taxes, premiums â†’ providers (FFS payments, MA capitation) â†’ also pays MA plans
- **Data Flow:** Generates â†’ claims databases (SEER-Medicare), coverage policies; Consumes â† quality data from providers

### 2.2 Commercial Payers
- **UnitedHealthcare** â€” Largest commercial; owns Optum (analytics, PBM, care delivery)
- **Elevance Health (Anthem/BCBS)** â€” Large BCBS licensee
- **Aetna (CVS Health)** â€” Integrated with CVS pharmacy/retail
- **Cigna (The Cigna Group)** â€” Owns Express Scripts (PBM)
- **Blue Cross Blue Shield** â€” Federation of 34 independent companies
- **Mechanisms:** Prior authorization, step therapy, clinical pathway compliance requirements, site-of-care steering
- **Pain Points:** Rising oncology drug costs, appropriate utilization management, member experience
- **RISA Opportunity:** â­ Prior auth automation (both provider-side and potentially payer-side), claims accuracy, pathway compliance documentation
- **Money Flow:** â† Employer/individual premiums â†’ providers (negotiated rates), pharma (rebates received)
- **Data Flow:** Generates â†’ EOBs, prior auth decisions, network data; Consumes â† claims from providers, clinical documentation

### 2.3 Medicaid
- **Role:** State-level, covers low-income; significant for certain cancers (cervical, late-stage presentations)
- **Structure:** 50 state programs + DC, managed Medicaid dominant
- **Pain Points:** Low reimbursement rates, state variation, complex eligibility
- **RISA Opportunity:** Eligibility verification, dual-eligible (Medicare + Medicaid) coordination
- **Money Flow:** â† Federal + state funding â†’ providers (low rates) â†’ managed Medicaid plans
- **Data Flow:** Generates â†’ state claims databases; Consumes â† eligibility data, provider claims

### 2.4 Specialty Pharmacy / PBMs
- **CVS Caremark** â€” Largest PBM
- **Express Scripts (Cigna)** â€” #2 PBM
- **Optum Rx (UnitedHealth)** â€” #3 PBM
- **Magellan Rx (Prime Therapeutics)** â€” Oncology specialty focus
- **Role:** Manage oral oncolytics (growing segment: ~40% of pipeline), specialty drug distribution, formulary management
- **Pain Points:** Oral parity laws, specialty drug costs, white/brown bagging policies
- **RISA Opportunity:** Oral oncolytic prior auth, benefits investigation automation, copay tracking
- **Money Flow:** â† Payer contracts, manufacturer rebates, spread pricing â†’ pharmacies (dispensing fees)
- **Data Flow:** Generates â†’ Rx claims, adherence data; Consumes â† prescriptions, formulary updates

### 2.5 Value-Based Care Programs
- **OCM (ended 2022) â†’ EOM (2023+)** â€” CMS episode-based oncology payment model
- **Bundled Payments** â€” Fixed payment for episode of care
- **Clinical Pathways:**
  - Via Oncology (Elsevier) â€” payer-aligned pathways
  - NCCN Guidelines â€” gold standard
  - Elsevier Clinical Pathways
  - Value Pathways (powered by NCCN)
- **Pain Points:** Attribution complexity, data reporting burden, measuring total cost of care
- **RISA Opportunity:** EOM performance tracking, pathway adherence documentation, episode cost analytics
- **Money Flow:** â† Performance bonuses from CMS/payers â†” risk-sharing (providers may owe money back)
- **Data Flow:** Generates â†’ quality measures, episode costs; Consumes â† claims, clinical data, benchmarks

---

## 3. ğŸ’Š PHARMA & BIOTECH (Drug Manufacturers)

### 3.1 Large Pharma Oncology
- **Merck** â€” Keytruda (#1 drug globally, ~$25B), immuno-oncology leader
- **Roche/Genentech** â€” Tecentriq, Herceptin franchise, Foundation Medicine
- **Bristol-Myers Squibb** â€” Opdivo, Revlimid, Abecma (CAR-T)
- **AstraZeneca** â€” Tagrisso, Imfinzi, Enhertu (with Daiichi Sankyo)
- **Pfizer** â€” Ibrance, Seagen acquisition (ADCs), Padcev
- **Novartis** â€” Kisqali, Kymriah (CAR-T), Pluvicto (radioligand)
- **Eli Lilly** â€” Verzenio, Retevmo, Jaypirca
- **Johnson & Johnson** â€” Darzalex, Carvykti (CAR-T with Legend)
- **AbbVie** â€” Imbruvica, Venclexta, Epcoritamab
- **Sanofi** â€” Sarclisa, Dupixent pipeline expansion
- **Revenue:** Oncology is #1 therapeutic area (~$220B+ globally, ~$90B US)
- **Pain Points:** Market access/formulary placement, real-world evidence generation, patient adherence, HCP engagement
- **RISA Opportunity:** Provider-side coding accuracy for branded drugs (ensures correct billing â†’ protects revenue), patient support program integration
- **Money Flow:** â†’ Distributors (WAC pricing) â†’ Providers (buy-and-bill markup) or PBMs/pharmacies (oral); â† Rebates to payers/PBMs; â†’ CROs (trial costs); â†’ Patient copay assistance
- **Data Flow:** Generates â†’ clinical trial data, drug labels; Consumes â† RWD (Flatiron, Tempus), claims data, prescribing patterns

### 3.2 Emerging Biotech
- **Cell Therapy / CAR-T:** Kite/Gilead (Yescarta), Novartis (Kymriah), BMS (Abecma, Breyanzi), Legend/J&J (Carvykti)
- **ADCs (Antibody-Drug Conjugates):** Seagen/Pfizer (Padcev, Adcetris), Daiichi Sankyo/AZ (Enhertu), Immunomedics/Gilead (Trodelvy)
- **Bispecifics:** Amgen (Blincyto, tarlatamab), Roche (Lunsumio), AbbVie (Epcoritamab)
- **Radiopharmaceuticals:** Novartis (Pluvicto), Point Biopharma, RayzeBio/BMS
- **Pain Points:** Reimbursement for novel modalities (CAR-T: $300K-$500K per treatment), J-code delays, site-of-care requirements
- **RISA Opportunity:** Novel therapy billing (CAR-T, ADCs have complex billing), pass-through payment tracking, miscellaneous J-code management

### 3.3 Biosimilars
- **Sandoz** â€” Trastuzumab, bevacizumab, rituximab biosimilars
- **Amgen** â€” Mvasi (bev), Kanjinti (tras)
- **Teva** â€” Herzuma (tras)
- **Coherus** â€” Udenyca (pegfilgrastim)
- **Fresenius Kabi** â€” Multiple biosimilars
- **Role:** Disrupting reference biologics; saving 15-40% on key drugs
- **Pain Points:** Payer formulary positioning, physician switching hesitancy, interchangeability status
- **RISA Opportunity:** Biosimilar vs. reference product billing accuracy, formulary-aware coding suggestions

### 3.4 Specialty Distributors (Big 3)
- **McKesson** â€” #1 distributor + US Oncology Network + GPO
- **Cencora (fka AmerisourceBergen)** â€” #2 distributor + specialty distribution
- **Cardinal Health** â€” #3 distributor + nuclear pharmacy (radiopharmaceuticals)
- **Role:** Drug distribution, buy-and-bill logistics, returns, specialty handling (cold chain for biologics)
- **Pain Points:** Supply chain disruptions, drug shortage management, narrow margins
- **RISA Opportunity:** Inventory-to-billing reconciliation, drug waste billing (JW modifiers), ASP-based reimbursement optimization
- **Money Flow:** â† Manufacturers (distribution fees, prompt pay) â†’ Providers (drug delivery); GPO rebates flow back to practices
- **Data Flow:** Generates â†’ purchasing/distribution data, 867 sales data; Consumes â† orders, formulary data

---

## 4. ğŸ§¬ DIAGNOSTICS & PRECISION MEDICINE

### 4.1 Genomic Testing / Companion Diagnostics (CDx)
- **Foundation Medicine (Roche)** â€” FoundationOne CDx (tissue), FoundationOne Liquid CDx
- **Tempus** â€” xT, xF, xR panels; AI-driven insights platform
- **Guardant Health** â€” Guardant360 (liquid biopsy), Shield (CRC screening)
- **Myriad Genetics** â€” BRACAnalysis, myChoice CDx, Precise MRD
- **NeoGenomics** â€” Specialty cancer testing lab
- **Natera** â€” Signatera (MRD/ctDNA monitoring), tumor-informed approach
- **Invitae** â€” Hereditary cancer panels (acquired by LabCorp 2024)
- **Role:** NGS panels, liquid biopsy, companion diagnostics, minimal residual disease (MRD) testing
- **Pain Points:** Coverage/reimbursement inconsistency, turnaround time, integrating results into EHR workflow, LCD variation by MAC
- **RISA Opportunity:** â­ Genomic test prior auth, coverage determination automation (LCD/NCD matching), ABN generation
- **Money Flow:** â† Payer reimbursement (often delayed/denied), provider orders, pharma CDx partnerships â†’ lab operations, R&D
- **Data Flow:** Generates â†’ genomic reports, variant data, treatment recommendations; Consumes â† clinical history, specimen data

### 4.2 Pathology / Lab
- **Quest Diagnostics** â€” National reference lab
- **Labcorp** â€” National reference lab + Invitae
- **Hospital-based pathology** â€” Integrated, faster TAT
- **Pain Points:** Pathologist shortage, digitization, standardization of reporting
- **RISA Opportunity:** Pathology billing accuracy (technical + professional components), CPT code selection for complex specimens

### 4.3 Imaging
- **Radiology Partners, RadNet, SimonMed** â€” Large radiology groups
- **PET/CT Centers** â€” Critical for staging, response assessment
- **Role:** Staging, treatment response monitoring, surveillance
- **Pain Points:** Prior auth burden (especially PET/CT), appropriate use criteria
- **RISA Opportunity:** Imaging prior auth automation, appropriate use criteria documentation

### 4.4 AI Diagnostics
- **Paige AI** â€” FDA-cleared AI for pathology (prostate, breast)
- **Lunit** â€” AI for radiology + pathology (Lunit INSIGHT)
- **PathAI** â€” AI-powered pathology, biopharma partnerships
- **Role:** Augmenting pathologist/radiologist reads, quantitative biomarker scoring
- **Pain Points:** Reimbursement for AI-assisted reads, clinical adoption, regulatory pathway
- **RISA Opportunity:** Billing for AI-assisted diagnostics (emerging CPT codes), coverage advocacy data

---

## 5. ğŸ”¬ CLINICAL TRIALS & RESEARCH

### 5.1 NCI / NIH
- **NCI** â€” ~$7B annual budget, funds cooperative groups
- **Cooperative Groups:** SWOG, ECOG-ACRIN, Alliance, NRG Oncology, Children's Oncology Group
- **Role:** Federal research funding, setting standards, population-level studies
- **Pain Points:** Slow enrollment, funding gaps, bureaucracy
- **RISA Opportunity:** Trial billing compliance (qualifying vs. routine costs), coverage analysis for investigational treatments

### 5.2 CROs (Contract Research Organizations)
- **IQVIA** â€” Largest; CRO + data + analytics
- **PPD (Thermo Fisher)** â€” Full-service CRO
- **Parexel** â€” Regulatory + clinical
- **Syneos Health (acquired by Elliott)** â€” Integrated biopharmaceutical solutions
- **Role:** Run pharma-sponsored trials, site management, data management, regulatory submissions
- **Pain Points:** Site identification, enrollment speed, data quality
- **RISA Opportunity:** Site feasibility data (billing patterns indicate treatment volumes), trial cost benchmarking

### 5.3 Decentralized Trial Platforms
- **Medidata (Dassault)** â€” Rave platform, decentralized trial modules
- **Veeva Systems** â€” Vault CTMS, eTMF, clinical data management
- **Science 37** â€” Virtual/hybrid trial execution
- **Pain Points:** Regulatory acceptance, data integrity, patient technology access
- **Data Flow:** Generates â†’ trial data, ePRO; Consumes â† EHR data, lab results

### 5.4 Trial Matching
- **Tempus** â€” AI-driven trial matching from genomic + clinical data
- **TrialJectory** â€” Patient-facing trial matching
- **Massive Bio** â€” AI trial matching for community oncology
- **RISA Opportunity:** Identifying trial-eligible patients from billing/clinical data patterns

### 5.5 Real-World Data / Evidence (RWD/RWE)
- **Flatiron Health (Roche)** â€” Gold standard oncology RWD; 280+ cancer clinics
- **Tempus** â€” Multimodal data (genomic + clinical + imaging)
- **ASCO CancerLinQ** â€” ASCO's data platform
- **Optum Labs** â€” Claims + EHR linked data
- **Komodo Health** â€” Patient journey analytics
- **Role:** Support regulatory decisions, label expansions, market access, HEOR
- **Pain Points:** Data quality, completeness, linkage across sources
- **RISA Opportunity:** Claims data enrichment for RWE (clean billing data = better RWD)

### 5.6 Philanthropic Research Accelerators
- **Parker Institute for Cancer Immunotherapy (PICI)** â€” Sean Parkerâ€“funded, immunotherapy focus
- **Stand Up to Cancer (SU2C)** â€” Dream Teams model, translational research
- **V Foundation** â€” 100% of donations to research
- **LLS (Leukemia & Lymphoma Society)** â€” Blood cancer research + patient support
- **Money Flow:** â† Donations â†’ research grants, clinical trials

---

## 6. ğŸ’» TECHNOLOGY & DATA

### 6.1 Oncology-Specific EHRs
- **Flatiron OncoEMR** â€” Purpose-built for oncology; strong in community practices
- **Varian ARIA (Siemens Healthineers)** â€” Radiation oncology OIS
- **Elekta MOSAIQ** â€” Radiation oncology OIS
- **iKnowMed (McKesson)** â€” US Oncology Network EHR
- **Epic Beacon** â€” Oncology module within Epic
- **Pain Points:** Interoperability, workflow burden, structured data capture, transition costs
- **RISA Opportunity:** â­ EHR integration for automated charge capture, clinical-to-billing data bridge

### 6.2 General EHRs in Oncology
- **Epic** â€” Dominant in large health systems; Beacon module for oncology
- **Oracle Health (Cerner)** â€” #2 EHR; oncology workflows
- **Role:** Core clinical documentation, orders, results
- **RISA Opportunity:** API integration (FHIR) for pulling clinical context into billing workflows

### 6.3 RCM / Billing
- **Waystar** â€” Claims management, prior auth, analytics (IPO 2024)
- **Availity** â€” Payer connectivity, eligibility, claims status
- **Change Healthcare (Optum/UHG)** â€” Largest claims clearinghouse (~50% of US claims)
- **R1 RCM** â€” End-to-end RCM outsourcing
- **Coronis Health** â€” RCM for specialty practices including oncology
- **Coding/Billing Firms:** TrueNorth, Oncology Analytics, ION Solutions
- **Pain Points:** â­ High denial rates (oncology denials 10-15%+), prior auth delays (avg 2-14 days), complex drug billing (buy-and-bill, waste, modifiers), staff burnout
- **RISA Opportunity:** â­â­ **CORE MARKET** â€” AI-powered denial prevention, prior auth automation, coding accuracy (chemo regimens, genomic tests, radiation), underpayment detection
- **Money Flow:** â† Provider fees (% of collections or per-claim) â†’ technology, staff
- **Data Flow:** Generates â†’ claims data, denial patterns, payment data; Consumes â† clinical documentation, payer rules, fee schedules

### 6.4 AI Companies in Oncology
- **Clinical AI:**
  - Tempus â€” Genomics + AI platform, clinical decision support
  - Flatiron Health â€” RWD analytics, clinical trial optimization
  - Paige AI â€” Digital pathology
  - Lunit â€” Radiology + pathology AI
  - PathAI â€” Pathology AI for biopharma
- **RCM AI:**
  - **RISA Labs** â€” Oncology-focused RCM AI â­
  - Waystar AI â€” Denial prediction, prior auth
  - Olive AI (shut down 2023) â€” Cautionary tale; over-promised automation
  - Akasa â€” RCM automation
  - AKASA, Infinx â€” Prior auth AI
- **Patient Access AI:**
  - Notable Health â€” Workflow automation, patient intake
  - Qventus â€” Operational AI, capacity optimization
  - Cedar â€” Patient financial engagement
- **Pain Points:** Integration complexity, trust/explainability, proving ROI
- **RISA Opportunity:** Differentiate via oncology domain depth (vs. horizontal RCM AI)

### 6.5 Radiation Oncology Technology
- **Varian (Siemens Healthineers)** â€” Linear accelerators, ARIA OIS, Ethos adaptive RT
- **Elekta** â€” Linacs, Unity MR-Linac, MOSAIQ OIS
- **ViewRay** â€” MRIdian MR-guided radiation (filed bankruptcy 2023, IP acquired)
- **Accuray** â€” CyberKnife, TomoTherapy
- **Role:** Treatment planning, delivery, quality assurance
- **Pain Points:** Complex billing (technical + professional, planning codes), machine utilization
- **RISA Opportunity:** Radiation oncology billing accuracy (one of the most complex billing areas in medicine)

### 6.6 Data Aggregators
- **Definitive Healthcare** â€” Provider intelligence, claims analytics
- **IQVIA** â€” Prescription + medical claims + clinical trial data
- **Komodo Health** â€” Healthcare map, patient journey analytics
- **Symphony Health (IQVIA)** â€” Prescription-level data
- **Truveta** â€” Health system consortium data
- **Role:** Market intelligence, targeting, outcomes research
- **RISA Opportunity:** Use aggregated data for benchmarking denial rates, identifying payer-specific patterns

---

## 7. âš–ï¸ REGULATORS & GUIDELINES

### 7.1 FDA
- **Role:** Drug/biologic approvals, breakthrough therapy designation, accelerated approval, CDx approvals
- **Key Oncology Actions:** RTOR (Real-Time Oncology Review), Project Orbis (international collaboration)
- **Impact on RISA:** New approvals â†’ new billing codes â†’ coding updates needed rapidly

### 7.2 CMS
- **Role:** Coverage determinations (NCD/LCD), payment models (OPPS, PFS, IPPS), quality programs (MIPS, APMs)
- **Key Programs:** EOM, MIPS oncology measures, radiation oncology APM (RO Model)
- **Impact on RISA:** â­ CMS rules directly drive billing complexity; policy changes = product updates

### 7.3 NCCN (National Comprehensive Cancer Network)
- **Role:** Gold-standard treatment guidelines; compendia listing drives coverage
- **NCCN Compendia:** Used by payers to determine drug coverage (off-label use)
- **Impact on RISA:** NCCN guideline alignment = basis for medical necessity / appeal documentation

### 7.4 ASCO / ESMO
- **ASCO** â€” Largest US oncology society; QOPI certification, guidelines, CancerLinQ
- **ESMO** â€” European counterpart, increasingly influential globally
- **QOPI** â€” Quality Oncology Practice Initiative (accreditation for practices)
- **Impact on RISA:** Quality metrics integration, guideline-based coding validation

### 7.5 State Regulators
- **Certificate of Need (CON)** â€” Limits new facilities in some states
- **Scope of Practice** â€” NP/PA prescribing, pharmacy compounding
- **Oral Parity Laws** â€” Require equal cost-sharing for oral vs. IV chemo (43+ states)
- **Impact on RISA:** State-specific billing rules, parity compliance tracking

### 7.6 Accreditation Bodies
- **Commission on Cancer (CoC) / ACS** â€” Hospital cancer program accreditation
- **QOPI Certification (ASCO)** â€” Practice-level quality
- **ACR (American College of Radiology)** â€” Imaging center accreditation
- **FACT** â€” Cellular therapy accreditation (CAR-T)
- **Impact on RISA:** Accreditation requirements drive documentation standards â†’ billing implications

---

## 8. ğŸ—ï¸ PATIENTS & ADVOCACY

### 8.1 Patient Advocacy Organizations
- **American Cancer Society (ACS)** â€” Largest; research funding, patient support, advocacy
- **Leukemia & Lymphoma Society (LLS)** â€” Blood cancer focus, copay assistance
- **Susan G. Komen** â€” Breast cancer
- **Pancreatic Cancer Action Network (PanCAN)** â€” Pancreatic cancer
- **LUNGevity** â€” Lung cancer
- **Colorectal Cancer Alliance** â€” CRC
- **Prostate Cancer Foundation** â€” Prostate cancer research
- **Role:** Awareness, research funding, policy advocacy, patient support
- **Pain Points:** Financial toxicity of cancer care, access disparities, navigating the system
- **RISA Opportunity:** Financial toxicity reduction through cleaner billing, accurate patient responsibility estimates

### 8.2 Patient Navigation
- **Navigators** â€” Nurse navigators, lay navigators (CoC requirement)
- **Social Workers** â€” Psychosocial support, resource connection
- **Financial Counselors** â€” Benefits verification, assistance programs, cost estimation
- **Pain Points:** Overwhelmed, manual processes, fragmented resources
- **RISA Opportunity:** â­ Automated financial counseling tools, real-time benefits verification, assistance program matching

### 8.3 Patient Support Programs (PSPs)
- **Manufacturer Copay Assistance** â€” Most branded oncolytics have copay cards/programs
- **Foundation Support:** PAN Foundation, HealthWell Foundation, CancerCare, NeedyMeds
- **Free Drug Programs:** Manufacturer Patient Assistance Programs (PAPs) for uninsured
- **Pain Points:** Complex applications, eligibility tracking, accumulator/maximizer adjuster programs
- **RISA Opportunity:** PSP enrollment automation, copay accumulator tracking, coordination of benefits

### 8.4 Survivorship
- **Role:** Long-term follow-up, late effects management, surveillance
- **Scale:** ~18 million cancer survivors in US (growing)
- **Pain Points:** Care plan transitions, primary care coordination, long-term monitoring costs
- **RISA Opportunity:** Survivorship billing (transition of care codes, screening schedules)

---

## 9. ğŸ“ˆ FINANCIAL / INVESTMENT

### 9.1 Private Equity in Oncology
- **TPG Capital** â€” OneOncology (largest PE-backed oncology platform)
- **Webster Equity Partners** â€” Urology/oncology practices
- **General Atlantic** â€” OneOncology investor
- **GenStar Capital** â€” Specialty practice investments
- **Trend:** Aggressive consolidation of community oncology; 2020-2025 saw rapid PE entry
- **Thesis:** Economies of scale, ancillary revenue, value-based care upside, eventual strategic exit
- **RISA Opportunity:** PE-backed platforms are sophisticated buyers seeking tech-enabled efficiency; natural channel partners

### 9.2 Venture Capital
- **Oncology AI investments:** Tempus ($6.1B valuation at IPO), Guardant ($3B+ market cap)
- **Digital health in oncology:** Navigating Cancer, Jasper Health, Canopy
- **RCM AI:** Waystar (IPO 2024), Akasa, Infinx
- **Trend:** Shift from hype to proof of ROI; focus on revenue-generating AI
- **RISA Opportunity:** Well-positioned in "practical AI" narrative (revenue impact, measurable ROI)

### 9.3 Public Markets
- **Tempus AI (TEM)** â€” IPO June 2024, genomics + AI platform
- **Guardant Health (GH)** â€” Liquid biopsy leader, Shield for screening
- **Exact Sciences (EXAS)** â€” Cologuard, Oncotype DX
- **Natera (NTRA)** â€” Signatera MRD, Panorama
- **Veracyte (VCYT)** â€” Genomic diagnostics
- **Waystar (WAY)** â€” RCM technology, IPO 2024
- **Trend:** Market rewards revenue growth + path to profitability; oncology data assets command premium valuations

---

## 10. ğŸ”„ RELATIONSHIP MAP â€” Key Flows

### Money Flows ğŸ’µ
```
Patient â”€â”€copay/coinsuranceâ”€â”€â†’ Provider
Payer â”€â”€reimbursementâ”€â”€â†’ Provider
CMS/Medicare â”€â”€FFS payments, EOM bonusesâ”€â”€â†’ Provider
Provider â”€â”€drug purchases (buy-and-bill)â”€â”€â†’ Distributor â”€â”€paymentâ”€â”€â†’ Pharma
Payer â”€â”€negotiated ratesâ”€â”€â†’ Specialty Pharmacy â”€â”€dispensingâ”€â”€â†’ Patient (oral drugs)
Pharma â”€â”€rebatesâ”€â”€â†’ Payer/PBM
Pharma â”€â”€copay assistanceâ”€â”€â†’ Patient (via foundations)
Pharma â”€â”€trial fundingâ”€â”€â†’ CRO â”€â”€site paymentsâ”€â”€â†’ Provider
PE/VC â”€â”€investmentâ”€â”€â†’ Oncology practices / Tech companies
Provider â”€â”€management feesâ”€â”€â†’ Network Orgs (US Oncology, OneOncology)
NCI/NIH â”€â”€grantsâ”€â”€â†’ Cancer Centers
Distributor â”€â”€GPO rebatesâ”€â”€â†’ Provider
```

### Data Flows ğŸ“Š
```
Provider â”€â”€claimsâ”€â”€â†’ Clearinghouse â”€â”€â†’ Payer
Provider â”€â”€clinical dataâ”€â”€â†’ EHR â”€â”€â†’ Data Aggregator (Flatiron, Tempus)
Diagnostics â”€â”€genomic reportsâ”€â”€â†’ Provider â”€â”€â†’ EHR
Payer â”€â”€remittance/ERAâ”€â”€â†’ Provider (RCM system)
Payer â”€â”€prior auth decisionsâ”€â”€â†’ Provider
Data Aggregator â”€â”€de-identified RWDâ”€â”€â†’ Pharma (market access, HEOR)
Data Aggregator â”€â”€benchmarksâ”€â”€â†’ Provider
NCCN â”€â”€guidelinesâ”€â”€â†’ Provider + Payer (coverage basis)
FDA â”€â”€approvals/labelsâ”€â”€â†’ All stakeholders
CMS â”€â”€coverage policies, fee schedulesâ”€â”€â†’ Provider + Payer
Provider â”€â”€quality measuresâ”€â”€â†’ CMS (MIPS, EOM)
Trial Platforms â”€â”€enrollment dataâ”€â”€â†’ Pharma/CRO
```

### Prior Authorization Flow ğŸ”„ (RISA Core Workflow)
```
1. Provider identifies treatment need (clinical)
2. Provider checks payer policy (coverage rules)
3. Provider submits prior auth request â†’ Payer
4. Payer reviews (clinical criteria, pathway, NCCN, LCD)
5. Payer approves/denies/pends â†’ Provider
6. If denied â†’ Provider appeals (peer-to-peer, clinical documentation)
7. Treatment administered â†’ Claim submitted
8. Claim adjudicated â†’ Payment or denial
9. If denied â†’ Appeal cycle begins again

RISA AI intervenes at steps 2, 3, 6, 7, 8, 9
```

### Buy-and-Bill Flow ğŸ’‰ (Infused Drugs â€” RISA Opportunity)
```
1. Provider purchases drug from Distributor (at ASP or GPO price)
2. Drug administered to patient in clinic/hospital
3. Provider bills payer: Drug (J-code) + Administration (CPT 96413-96417)
4. Payer reimburses at ASP + 6% (Medicare) or contracted rate (commercial)
5. Margin = Reimbursement âˆ’ Acquisition cost
6. Provider also bills for waste (JW modifier) if applicable

RISA AI optimizes: J-code accuracy, waste billing, NDC-to-HCPCS mapping, ASP monitoring
```

---

## 11. ğŸ¯ RISA LABS â€” STRATEGIC OPPORTUNITY SUMMARY

### Primary Target Segments (by revenue opportunity)
1. **Large Community Oncology Practices** â€” Highest volume, most billing complexity, margin-sensitive
2. **Oncology Network Organizations** â€” Platform deals (one contract â†’ hundreds of practices)
3. **Hospital System Cancer Programs** â€” Large but slower sales cycle
4. **Academic Medical Centers** â€” Complex billing, prestige customers

### Key RISA Value Propositions
| Capability | Stakeholder Impact |
|---|---|
| **Prior Auth Automation** | Reduces 2-14 day delays â†’ faster treatment, less staff burden |
| **Denial Prevention** | Prevents 10-15% denial rate â†’ immediate revenue recovery |
| **Coding Accuracy** | Correct J-codes, modifiers, regimen billing â†’ reduces under/over-coding risk |
| **Drug Billing Optimization** | Buy-and-bill margin protection, waste billing, ASP monitoring |
| **Genomic Test Coverage** | LCD/NCD matching for molecular diagnostics â†’ faster test approvals |
| **EOM/VBC Reporting** | Automated quality measures, episode cost tracking |
| **Appeals Intelligence** | AI-generated appeal letters with clinical evidence â†’ higher overturn rates |

### Competitive Moat Opportunities
- **Oncology domain depth** â€” Horizontal RCM AI (Waystar, Akasa) lacks onc-specific logic
- **Regimen-aware billing** â€” Understanding multi-drug protocols, cycling, dose modifications
- **Payer policy intelligence** â€” Real-time oncology LCD/NCD/pathway tracking
- **Network effects** â€” More practices â†’ better denial prediction models â†’ more practices

---

*This market map is designed for conversion to a Whimsical mind map. Each numbered section = a primary branch. Subsections = child nodes. Bullet points = leaf nodes with detail.*
